Life sciences company 🇺🇸, United States
Revvity supplies tools and services for life sciences research and diagnostics. Its planned acquisition of Human Cell Design would add human-relevant cell models used in metabolic-disease research, including GLP-1 drug discovery. This profile follows its deals and the development of its research and discovery business.
Market cap not yet added.
Last 12 months
Last 12 months
Revvity agreed to acquire Human Cell Design, adding human-relevant cell models used in diabetes, obesity and GLP-1 drug discovery. Financial terms were not disclosed.
RevvityGrow revenue at each location and build a commercial model that can scale across a clinic group.
Sanor never sells your personal information. By providing this information you agree to Sanor’s Privacy Policy and Terms of Service.
SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.
SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.
All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.
